1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next-Generation Bispecific Antibody Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next-Generation Bispecific Antibody Market, by Antibody Format
8.1.1. IgG-like Bispecific Antibodies
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-IgG-like/Fragment-based Bispecifics
8.1.2.1. Market Revenue and Forecast
8.1.3. Multispecific/Engineered Next-Gen Formats
8.1.3.1. Market Revenue and Forecast
9.1. Next-Generation Bispecific Antibody Market, by Mechanism of Action
9.1.1. T-cell Engagers (CD3-based)
9.1.1.1. Market Revenue and Forecast
9.1.2. Dual Immune Checkpoint Targeting
9.1.2.1. Market Revenue and Forecast
9.1.3. Dual Tumor Antigen Targeting
9.1.3.1. Market Revenue and Forecast
9.1.4. Immune Cell Engagers (NK cell, macrophage)
9.1.4.1. Market Revenue and Forecast
10.1. Next-Generation Bispecific Antibody Market, by Therapeutic Application
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Autoimmune & Inflammatory Diseases
10.1.2.1. Market Revenue and Forecast
10.1.3. Hematology (Non-oncology)
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Emerging Indications
10.1.4.1. Market Revenue and Forecast
11.1. Next-Generation Bispecific Antibody Market, by Target Type
11.1.1. Tumor Antigen × Immune Cell Targets
11.1.1.1. Market Revenue and Forecast
11.1.2. Dual Tumor Antigen Targets
11.1.2.1. Market Revenue and Forecast
11.1.3. Immune Checkpoint × Immune Checkpoint Targets
11.1.3.1. Market Revenue and Forecast
11.1.4. Cytokine/Growth Factor Targets
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Antibody Format
12.1.2. Market Revenue and Forecast, by Mechanism of Action
12.1.3. Market Revenue and Forecast, by Therapeutic Application
12.1.4. Market Revenue and Forecast, by Target Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Antibody Format
12.1.5.2. Market Revenue and Forecast, by Mechanism of Action
12.1.5.3. Market Revenue and Forecast, by Therapeutic Application
12.1.5.4. Market Revenue and Forecast, by Target Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Antibody Format
12.1.6.2. Market Revenue and Forecast, by Mechanism of Action
12.1.6.3. Market Revenue and Forecast, by Therapeutic Application
12.1.6.4. Market Revenue and Forecast, by Target Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Antibody Format
12.2.2. Market Revenue and Forecast, by Mechanism of Action
12.2.3. Market Revenue and Forecast, by Therapeutic Application
12.2.4. Market Revenue and Forecast, by Target Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Antibody Format
12.2.5.2. Market Revenue and Forecast, by Mechanism of Action
12.2.5.3. Market Revenue and Forecast, by Therapeutic Application
12.2.5.4. Market Revenue and Forecast, by Target Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Antibody Format
12.2.6.2. Market Revenue and Forecast, by Mechanism of Action
12.2.6.3. Market Revenue and Forecast, by Therapeutic Application
12.2.6.4. Market Revenue and Forecast, by Target Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Antibody Format
12.2.7.2. Market Revenue and Forecast, by Mechanism of Action
12.2.7.3. Market Revenue and Forecast, by Therapeutic Application
12.2.7.4. Market Revenue and Forecast, by Target Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Antibody Format
12.2.8.2. Market Revenue and Forecast, by Mechanism of Action
12.2.8.3. Market Revenue and Forecast, by Therapeutic Application
12.2.8.4. Market Revenue and Forecast, by Target Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Antibody Format
12.3.2. Market Revenue and Forecast, by Mechanism of Action
12.3.3. Market Revenue and Forecast, by Therapeutic Application
12.3.4. Market Revenue and Forecast, by Target Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Antibody Format
12.3.5.2. Market Revenue and Forecast, by Mechanism of Action
12.3.5.3. Market Revenue and Forecast, by Therapeutic Application
12.3.5.4. Market Revenue and Forecast, by Target Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Antibody Format
12.3.6.2. Market Revenue and Forecast, by Mechanism of Action
12.3.6.3. Market Revenue and Forecast, by Therapeutic Application
12.3.6.4. Market Revenue and Forecast, by Target Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Antibody Format
12.3.7.2. Market Revenue and Forecast, by Mechanism of Action
12.3.7.3. Market Revenue and Forecast, by Therapeutic Application
12.3.7.4. Market Revenue and Forecast, by Target Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Antibody Format
12.3.8.2. Market Revenue and Forecast, by Mechanism of Action
12.3.8.3. Market Revenue and Forecast, by Therapeutic Application
12.3.8.4. Market Revenue and Forecast, by Target Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Antibody Format
12.4.2. Market Revenue and Forecast, by Mechanism of Action
12.4.3. Market Revenue and Forecast, by Therapeutic Application
12.4.4. Market Revenue and Forecast, by Target Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Antibody Format
12.4.5.2. Market Revenue and Forecast, by Mechanism of Action
12.4.5.3. Market Revenue and Forecast, by Therapeutic Application
12.4.5.4. Market Revenue and Forecast, by Target Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Antibody Format
12.4.6.2. Market Revenue and Forecast, by Mechanism of Action
12.4.6.3. Market Revenue and Forecast, by Therapeutic Application
12.4.6.4. Market Revenue and Forecast, by Target Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Antibody Format
12.4.7.2. Market Revenue and Forecast, by Mechanism of Action
12.4.7.3. Market Revenue and Forecast, by Therapeutic Application
12.4.7.4. Market Revenue and Forecast, by Target Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Antibody Format
12.4.8.2. Market Revenue and Forecast, by Mechanism of Action
12.4.8.3. Market Revenue and Forecast, by Therapeutic Application
12.4.8.4. Market Revenue and Forecast, by Target Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Antibody Format
12.5.2. Market Revenue and Forecast, by Mechanism of Action
12.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.4. Market Revenue and Forecast, by Target Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Antibody Format
12.5.5.2. Market Revenue and Forecast, by Mechanism of Action
12.5.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.5.4. Market Revenue and Forecast, by Target Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Antibody Format
12.5.6.2. Market Revenue and Forecast, by Mechanism of Action
12.5.6.3. Market Revenue and Forecast, by Therapeutic Application
12.5.6.4. Market Revenue and Forecast, by Target Type
13.1. Novartis
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sanofi
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Roche
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Pfizer
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Celgene Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Johnson & Johnson
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Regeneron Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. GSK plc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
